From mboxrd@z Thu Jan 1 00:00:00 1970 Return-Path: Received: (qmail 11713 invoked by alias); 5 Oct 2005 11:11:10 -0000 Mailing-List: contact rda-help@sources.redhat.com; run by ezmlm Precedence: bulk List-Subscribe: List-Post: List-Help: , Sender: rda-owner@sources.redhat.com Received: (qmail 11696 invoked by uid 22791); 5 Oct 2005 11:11:09 -0000 Received: from [218.111.219.67] (HELO emails.de) (218.111.219.67) by sourceware.org (qpsmtpd/0.30-dev) with SMTP; Wed, 05 Oct 2005 11:11:09 +0000 Message-ID: From: "Meredith Sutherland" To: rda@sources.redhat.com Subject: Watch this St0ckTcrade Date: Wed, 05 Oct 2005 11:11:00 -0000 X-Priority: 3 X-MSMail-Priority: Normal X-Mailer: Microsoft Outlook Express 6.00.2600.0000 X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2600.0000 Mime-Version: 1.0 Content-Transfer-Encoding: 7bit Content-Type: text/plain; charset=iso-8859-1 X-SW-Source: 2005-q4/txt/msg00000.txt.bz2 ATTENTION INVESTING PUBLIC ASCE . PK Recent Trading Range: $.80 - $.90 Expected Trading Range: $1.50 - $2.00 ASCE . PK BELLEVUE, WA. September 14, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious pharmaceuticals, compounds and other products, announces it has received an initial commitment for up to $1 million in funding for continued research particularly in anti-cancer compounds and for organizational growth. BELLEVUE, WA. September 27th, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious pharmaceuticals, compounds and other products, announces the addition of Dr. Philip Mease to its Scientific Advisory Board. Dr. James Clagett, President and CEO of Ascentia said, .We are privileged to have such an internationally recognized rheumatologist who has a distinguished career in the clinical development of therapies for rheumatic diseases. Dr. Mease.s experience in clinical drug discovery along with his respected relationship with drug regulatory agencies will greatly assist Ascentia in its drug discovery and commercialization program.. Dr. Mease is Chief of the Rheumatology Clinical Research Division at Swedish Hospital, Clinical Professor at the University of Washington, and founder of Seattle Rheumatology Associates. Dr. Mease graduated from Stanford University Medical School and completed his medical training at University of Washington, Seattle. About Ascentia Biomedical Corporation Our focus is SOLUTIONS through RESEARCH and DISCOVERY. Ascentia is developing and commercializing new pharmaceutical and biomedical products for application in a number of areas, including treatment for asthma, arthritis, psoriasis and cancer. Initially, a majority of these products will be secured through direct purchase or through licensing. As the Company grows and evolves, more products will be developed internally. Ascentia is focused on therapies for cancer and diseases of inflammation. Forward-Looking Statements This release may contain forward-looking statements that involve risks and uncertainties. These statements do not constitute representations or promises. Rather, these statements express opinions, hopes and desires that may not be based on objective or factual criteria or measurable results. No one should rely on such statements for any purpose except as specifically stated To get taken off the list email NOSTK@Yahoo.com